In vivo visualisation of nanoparticle entry into central nervous system tissue

Archives of Toxicology

Volumn 86, Issue 7, 2012, Pages 1099-1105

  Henrich Noack, Petra ^a   Prilloff, Sylvia ^a   Voigt, Nadine ^a   Jin, Jing ^a   Hintz, Werner ^a   Tomas, Jürgen ^a   Sabel, Bernhard A ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Blood brain barrier; Blood retina barrier; Brain; In vivo confocal neuroimaging; Polybutyl cyanoacrylate nanoparticles

Indexed keywords

NANOPARTICLE; POLYBUTYL CYANOACRYLATE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL FATE; CELL LABELING; CELL LOSS; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CYTOTOXICITY; FLUORESCENCE ANALYSIS; IN VIVO STUDY; MOLECULAR INTERACTION; NANOANALYSIS; NERVOUS TISSUE; NEUROIMAGING; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; STEREOTACTIC PROCEDURE; SUPERIOR COLLICULUS; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; BLOOD-RETINAL BARRIER; CELL DEATH; ENBUCRILATE; FLUORESCENT DYES; INJECTIONS, INTRAVENOUS; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; NANOPARTICLES; PARTICLE SIZE; PHOTOMICROGRAPHY; RATS; RATS, INBRED STRAINS; RETINA; RETINAL GANGLION CELLS; RETINAL VESSELS; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

EID: 84866034912     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-012-0832-4     Document Type: Article

References (28)

1. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deWcient mice. J Cereb Blood Flow Metab 20:381-386
2. Darius J, Meyer FP, Sabel BA, Schroder U (2000) InXuence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol 52:1043-1047
3. Elmquist WF, Sawchuk RJ (1997) Application of microdialysis in pharmacokinetic studies. Pharm Res 14:267-288
4. Engelhardt B (2003) Development of the blood-brain barrier. Cell Tissue Res 314(1):119-129
5. Kreuter J (2004) Nanoparticles as drug delivery system. In: Nalwa HS (ed) Encyclopedia of nanoscience and nanotechnology, vol 7. American ScientiWc Publishers, New York, pp 161-180
6. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch- Brandt C, Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317-325
7. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ (2003) Direct evidence that polysorbate-80-coated poly(butylcanacrylate) nanoparticles deliver drugs ti the CNS via speciWc mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409-416
8. O'Sullivan C, Birkinshaw C (2002) Hydrolysis of poly (n- butylcyanacrylate) nanoparticles using esterase. Polym Degrad Stab 78:7-15
9. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C (2004) Translocation of inhaled ultraWne particles to the brain. Inhal Toxicol 16:437-445
10. Pardridge WM (ed) (1998) Introduction to the blood-brain barrier: methodology, biology and pathology. University Press, Cambridge
11. Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139
12. Prilloff S, Noblejas MI, Chedhomme V, Sabel BA (2007) Two faces of calcium activation after optic nerve trauma: life or death of retinal ganglion cells in vivo depends on calcium dynamics. Eur J Neurosci 25:3339-3346
13. Prilloff S, Fan Y, Henrich-Noack P, Sabel BA (2010) In vivo confocal neuroimaging (ICON: non-invasive, functional imaging of the mammalian CNS with cellular resolution. Eur J Neurosci 31: 521-528
14. Reichel A (2006) The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab 7:184-203
15. Reichel A, Begley DJ, Abott NJ (2003) The blood-brain barrier: biology and research protokolls. In: Nag S (ed) Methods in molecular medicine. Humana Press, New York, pp 309-326
16. Reimold I, Domke D, Bender J, Seyfried CA, Radunz HE, Fricker G (2008) Delivery of nanoparticles to the brain detected by Xuorescence microscopy. Eur J Pharm Biopharm 70:627-632
17. Rousseau V, Sabel BA (2001) Restoration of vision IV: role of compensatory some cell swelling of surviving retinal ganglion cells in recovery of vision after optic nerve crush. Restor Neurol Neurosci 18:177-189
18. Rousseau V, Engelmann R, Sabel BA (1999) Restoration of vision III: soma swelling dynamics predicts neuronal death or survival after optic nerve crush in vivo. NeuroReport 10:3387-3391
19. Sabel BA, Engelmann R, Humphrey MM (1997) In vivo confocal neuroimaging of CNS neurons (ICON). Nat Med 3:244-247
20. Saunders NR, Habgood MD, Dziegielewska KM (1999) Barrier mechanisms in the brain. Clin Exp Pharmacol Physiol 26:11-19
21. Sautter J, Sabel BA (1993) Recovery of brightness discrimination in adult rats despite progressive loss of retrogradely labelled retinal ganglion cells after controlled optic nerve crush. Eur J Neurosci 5:680-690
22. Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA (2008) Brain tumour therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195:21-27
23. Schröder U, Sabel BA (1996) Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic eVects of i.v. dalargin injections. Brain Res 710:121-124
24. Schröder U, Schröder H, Sabel BA (2000) Body distribution of 3H-labelled dalargin bound to poly(butyl cyanacrylate) nanoparticles after i.v. injection in mice. Life Sci 66:495-502
25. Sommerfeld P, Sabel BA, Schroeder U (2000) Long-term stability of PBCA nanoparticle suspensions. J Microencapsul 17:69-79
26. Steuer H, Jaworski A, Stoll D, Schlosshauer B (2004) In vitro model of the outer blood-retina barrier. Brain Res Protoc 13:26-36
27. Steuer H, Jaworski A, Elger B, Kaussmann M, Keldenich J, Schneider H, Stoll D, Schlosshauer B (2005) Functional characterization and comparison of the outer blood-retina barrier and the bloodbrain barrier. Invest Ophthalmol Vis Scie 46:1047-1053
28. Zhou Q, Sun X, Zenf L, Liu J, Zhang Z (2009) A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine 5:419-423